Novocain 0,5% 5ml #10
10 ampoules 2 ml
Local anesthetic agent with mild anesthetic activity and a large breadth of therapeutic action. Lowers the excitability of motor cortical areas of the brain infarction and peripheral cholinoreactive systems, has a blocking effect on the autonomic ganglia, reduces smooth muscle spasms, reduces the formation of acetylcholine.
In the body relative to procaine is rapidly hydrolyzed by plasma esterases, involvement of blood and tissues. The products of enzymatic hydrolysis are the P-aminobenzoic acid and dietilaminoetanol. A urine excreted 80% of the drug.
Indications for use
Infiltration, conduction, epidural and spinal anesthesia; perirenal block, for the potentiation of the main drugs for general anesthesia for the relief of pain of various origins.
Dosage and administration
Number of novocaine-Darnitsa and overall the dose depends on the type of anesthesia and the nature of surgical intervention. To block anesthesia using 2% solution, for an epidural - 20 - 25 ml of 2% solution. For spinal anesthesia using 1-5% solution of 2-3 ml. When perirenal blockade in the perirenal tissue injected 50-80 mL of 0.5% solution of novocaine-Darnitsa. Solutions of Novocaine-Darnitsa also used intravenously and orally (hypertension, toxemia of pregnancy with hypertensive syndrome, spasms of blood vessels, phantom pain, peptic ulcer and duodenal ulcer, ulcerative colitis, pruritus, dermatitis, eczema, keratitis, iridocyclitis, glaucoma, etc ..) In the vein type from 1 to 10 to 15 ml of 0.5% solution (slow, best in isotonic sodium chloride solution). The number of injections depends on the severity of the disease and the effect of therapy. Inside using 0.5% solution of 30-50 ml 2-3 times a day. Subcutaneous injections of 0.5% solution is used for circular and paravertebral blockade with eczema, neurodermatitis, sciatica, etc. Higher doses for adults: intramuscular injection - a single 0.1 g daily - 0.1 g, intravenously - a single 0.05 g, daily - 0.1 g; inside - single 0.25 grams daily - 0.75, the
Dizziness, weakness, hypotension, allergic reactions such as urticaria. Perhaps the development of anaphylactic shock
Hypersensitivity to the drug, myasthenia gravis, hypotension, treatment, sulfonamides, purulent process in the injection site; prescribed with caution in severe diseases of the heart, liver and kidneys.
Interaction with other medicinal products
Atropine sulphate enhances the anesthetic effect of novocaine-Darnitsa. Novocaine-Darnitsa attenuates diuretic effect of diuretics. In combination with salicylates, sulfanilamidnymi drugs decreases as bacteriostatic and anesthetic effect.
In case of overdose observed motor agitation, respiratory depression, hypotension, epileptiform convulsions, dyspnea, collapse, rash, edema (allergic reaction). As the concentration increases the toxicity. Treatment: symptomatic of indications, including artificial respiration, anticonvulsants, in the collapse - blood fluids intravenously, in disorders of cardiac activity - appropriate resuscitation.
Features of the application
With increasing concentration of total drug dose is reduced. To reduce the suction and elongation under local anesthetic to the solution of novocaine-Darnitsa added a solution of epinephrine hydrochloride 0.1% and 1 drop per ml of preparation 02/05/10. To reveal the sensitivity produce intradermal tests (swelling and redness around the injection site), sometimes with this test can be the general reaction, use of the drug is also used in small doses: intramuscularly administered first 2 ml of 2% solution, after 3 days with no side effects - 3 ml of this solution and then proceed to a full dose - 5 ml per injection.
Terms and Conditions of storage
Store in a dark place. Shelf life - listed on the packaging.
Of 10 vials per pack